LAP016B
Drug
Novartis Pharma AG
Total Payments
$238,087
Transactions
8
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $59,406 | 2 | 0 |
| 2017 | $178,681 | 6 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $237,937 | 3 | 99.9% |
| Food and Beverage | $149.95 | 5 | 0.1% |
Payments by Type
Research
$237,937
3 transactions
General
$149.95
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CLAP016B2301 | Novartis Pharma AG | $237,937 | 0 |
Top Doctors Receiving Payments for LAP016B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, MN | $237,937 | 3 |
| , M.D | Hematology & Oncology | Jacksonville, FL | $29.99 | 1 |
| , M.D | Cytopathology | Houston, TX | $29.99 | 1 |
| , M.D., D.PHIL | Medical Oncology | New Haven, CT | $29.99 | 1 |
| , M.D | Medical Oncology | Rockville, MD | $29.99 | 1 |
| , MD | Anatomic Pathology | New Haven, CT | $29.99 | 1 |
Ad
Manufacturing Companies
- Novartis Pharma AG $238,087
Product Information
- Type Drug
- Total Payments $238,087
- Total Doctors 5
- Transactions 8
About LAP016B
LAP016B is a drug associated with $238,087 in payments to 5 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $59,406 was paid across 2 transactions to 0 doctors.
The most common payment nature for LAP016B is "Unspecified" ($237,937, 99.9% of total).
LAP016B is associated with 1 research study, including "CLAP016B2301" ($237,937).